## CLAIMS

What is claimed is:

1. A method of administering botulinum toxin to achieve a cosmetic effect to an individual in need thereof, the method comprising:

injecting an effective amount of a botulinum toxin composition into the individual to achieve a cosmetic effect,

wherein the botulinum toxin composition comprises

a positively charged carrier comprising the amino acid sequence RKKRRQRRRG-$(K)_n$-GRKKRRQRRR, wherein n is selected from 10 to 23, and,

a botulinum toxin component present in an amount suitable for injection, the botulinum toxin component selected from the group consisting of a botulinum toxin complex, reduced botulinum toxin complex, and botulinum toxin, and

a pharmaceutically acceptable diluent suitable for injection,

wherein the positively charged carrier is non-covalently associated with the botulinum toxin component.

2. The method according to claim 1, wherein the cosmetic effect is decreasing the appearance of fine lines and/or wrinkles.

3. Use of a botulinum toxin composition in the manufacture of a medicament for achieving a therapeutic effect to an individual in need thereof, wherein the botulinum toxin composition comprises

a positively charged carrier comprising the amino acid sequence RKKRRQRRRG-(K)n-GRKKRRQRRR, wherein n is selected from 10 to 23, and

a botulinum toxin component present in an amount suitable for injection, the botulinum toxin component selected from the group consisting of a botulinum toxin complex, reduced botulinum toxin complex, and botulinum toxin, and

a pharmaceutically acceptable diluent suitable for injection,

wherein the positively charged carrier is non-covalently associated with the botulinum toxin component, and

wherein the therapeutic effect is reducing or enhancing immune response or reduction of a symptom associated with a disorder selected from the group consisting of muscle tension, muscle spasm, hemifacial spasm, adult onset spasmodic torticollis, anal fissure, blepharospasm, cerebral palsy, headaches, migraine headache, strabismus, temporomandibular joint disorder, neurologic pain, overactive bladder, rhinitis, sinusitis, acne, dystonia, dystonic contractions, hyperhidrosis, and hypersecretion of a gland controlled by the cholinergic nervous system.

4. The method according to claim 1 or 2 or the use according to claim 3, wherein said botulinum toxin component is present in said composition in an amount from 1 to 200 U per injection.

5. The method according to claim 1 or 2 or the use according to claim 3, wherein said botulinum toxin component is present in said composition in an amount from 10 to 200 U per injection.

6. The method according to claim 1 or 2 or the use according to claim 3, wherein said botulinum toxin component is present in said composition in an amount from 30 to 200 U per injection.

7. The method or use according to any one of claims 1 to 6, wherein said composition comprises 1.0 pg to 0.5 mg of positively charged carrier per unit of botulinum toxin.

8. Use of a botulinum toxin composition in the manufacture of a medicament for reducing or preventing muscle spasm in an individual in need thereof,

wherein the botulinum toxin composition is to be injected into the individual, at an area affected by muscle spasm, to reduce or prevent said muscle spasm, wherein the botulinum toxin composition comprises a positively charged carrier comprising the amino acid sequence

RKKRRQRRRG-$(K)_n$-GRKKRRQRRR, wherein n is selected from 10 to 23, and, a botulinum toxin component present in an amount suitable for injection, the botulinum toxin component selected from the group consisting of a botulinum toxin complex, reduced botulinum toxin complex, and botulinum toxin, and a pharmaceutically acceptable diluent suitable for injection;

wherein the positively charged carrier is non-covalently associated with the botulinum toxin component.

9. The use according to claim 8, wherein the reduction or prevention of muscle spasm results from local muscle paralysis following injection of said composition and wherein said local muscle paralysis lasts longer than local muscle paralysis following injection of a composition of the same dose of units of botulinum toxin consisting of type A botulinum toxin with accessory protein, 0.5 mg of human albumin, and 0.9 mg of sodium chloride.

10. The use according to claim 8 or 9, wherein the muscle spasm is associated with at least one condition selected from the group consisting of hemifacial spasm, adult onset spasmodic torticollis, anal fissure, blepharospasm, strabismus, temporomandibular joint disorder, overactive bladder, facial muscle spasm, muscular cramp, muscular ache, dystonia, cervical dystonia, and dystonic contraction.

11. The use according to any one of claims 8 to 10, wherein said botulinum toxin component is present in said composition in an amount from 30 to 200 U per injection.

12. A sterile injectable composition for administration by injection to achieve a therapeutic or cosmetic effect in a subject in need thereof, the composition comprising:

a botulinum toxin component present in an amount suitable for injection, the botulinum toxin component selected from the group consisting of a botulinum complex, a reduced botulinum toxin complex, and a botulinum toxin; and

a positively charged carrier comprising the amino acid sequence RKKRRQRRRG-$(K)_n$-GRKKRRQRRR, wherein n is selected from 10 to 23;

wherein the botulinum toxin component is non-covalently associated with the positively charged carrier, and

a pharmaceutically or cosmeceutically acceptable diluent suitable for injection.

13. The composition according to claim 12, wherein the cosmetic effect is a reduction in the appearance of wrinkles.

14. The composition according to claim 12, wherein the therapeutic effect is a reduction of a symptom associated with a disorder selected from the group consisting of hemifacial spasm, adult onset spasmodic torticollis, anal fissure, blepharospasm, cerebral palsy, headaches, strabismus, temporomandibular joint disorder, neurologic pain, overactive bladder, rhinitis, sinusitis, acne, dystonia, dystonic contractions, hyperhidrosis, and hypersecretion of a gland controlled by the cholinergic nervous system.

15. A syringe comprising:

a botulinum toxin component present in an amount suitable for injection, the botulinum toxin component selected from the group consisting of a botulinum complex, a reduced botulinum toxin complex, and a botulinum toxin; and

a positively charged carrier comprising the amino acid sequence RKKRRQRRRG-$(K)_n$-GRKKRRQRRR, wherein n is selected from 10 to 23;

wherein the botulinum toxin component is non-covalently associated with the positively charged carrier, and

a pharmaceutically or cosmeceutically acceptable diluent suitable for injection.

16. A reconstituted botulinum toxin composition comprising:

a botulinum toxin component present in an amount suitable for injection, the botulinum toxin component selected from the group consisting

of a botulinum complex, a reduced botulinum toxin complex, and a botulinum toxin; and

a positively charged carrier comprising the amino acid sequence RKKRRQRRRG-$(K)_n$-GRKKRRQRRR, wherein n is selected from 10 to 23; and

a pharmaceutically acceptable aqueous liquid diluent, and

wherein the botulinum toxin component is non-covalently associated with the positively charged carrier.

17. The composition according to claim 16, wherein the reconstituted botulinum toxin composition has a viscosity in the range of about 0.4 to about 2.0 cP.

18. The method, use, composition, or syringe according to any one of claims 1 to 17, wherein the botulinum toxin complex, reduced botulinum toxin complex or botulinum toxin is obtained from serotypes A or B of C. botulinum.

19. The method, use, composition, or syringe according to any one of claims 1 to 17, wherein the botulinum toxin component is a type A botulinum toxin and 150 kD.

20. The method, use, composition, or syringe according to any one of claims 1 to 5, 7 to 10, and 12 to 19, wherein said botulinum toxin component is present in said composition in an amount of 10 U per injection.

21. The method, use, composition, or syringe according to any one of claims 1 to 19, wherein said botulinum toxin component is present in said composition in an amount of 30 U per injection.